Search

Your search keyword '"Mostafid, Hugh"' showing total 134 results

Search Constraints

Start Over You searched for: Author "Mostafid, Hugh" Remove constraint Author: "Mostafid, Hugh"
134 results on '"Mostafid, Hugh"'

Search Results

101. Correction to: Meeting abstracts from the 4th International Clinical Trials Methodology Conference (ICTMC) and the 38th Annual Meeting of the Society for Clinical Trials

102. Management of NMIBCduring BCGshortage and COVID‐19

103. Alternating Cystoscopy with Bladder EpiCheck ®in the Surveillance of Low-Grade Intermediate-Risk NMIBC: A Cost Comparison Model

105. Is 4 days hospital stay post robotic radical cystectomy feasible; A multidisciplinary enhanced recovery program after minimal invasive surgery challenge

107. Reply to Harry Herr's Letter to the Editor re: Marko Babjuk, Andreas Böhle, Maximilian Burger, et al. EAU Guidelines on Non–muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016. Eur Urol 2017;71:447–61

109. PD19-08 RADIOFREQUENCY-INDUCED THERMO-CHEMOTHERAPY EFFECT (RITE) PLUS MITOMYCIN VERSUS A SECOND COURSE OF BACILLUS CALMETTE-GUÉRIN (BCG) OR INSTITUTIONAL STANDARD IN PATIENTS WITH RECURRENCE OF NON-MUSCLE INVASIVE BLADDER CANCER FOLLOWING INDUCTION OR MAINTENANCE BCG THERAPY (HYMN): A OPEN-LABEL, MULTICENTRE, PHASE III RANDOMISED CONTROLLED TRIAL

110. Does urinary cytology have a role in haematuria investigations?

111. Recruitment aids for a phase II randomised trial in low risk bladder cancer

112. Phase I/II canon study: Oncolytic immunotherapy for the treatment of non-muscle invasive bladder (NMIBC) cancer using intravesical coxsackievirus A21.

113. Oncolytic immunotherapy for the treatment of non-muscle invasive bladder cancer using intravesical coxsackievirus A21

123. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one: National Harbor, MD, USA. 9-13 November 2016

124. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

125. Corrigendum to 'EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort Under the Auspices of the EAU-ESMO Guidelines Committees' [European Urology 77 (2020) 223-250]

127. Reply.

128. Developing a Diagnostic Multivariable Prediction Model for Urinary Tract Cancer in Patients Referred with Haematuria: Results from the IDENTIFY Collaborative Study

129. Indications and complications of androgen deprivation therapy

130. Prevention of bladder cancer incidence and recurrence

131. Unmet Need in Non-muscle-invasive Bladder Cancer Failing Bacillus Calmette-Guérin Therapy: A Systematic Review and Cost-effectiveness Analyses from the International Bladder Cancer Group.

132. Alternating Cystoscopy with Bladder EpiCheck ® in the Surveillance of Low-Grade Intermediate-Risk NMIBC: A Cost Comparison Model.

133. Guideline of guidelines: asymptomatic microscopic haematuria.

134. Prevention of bladder cancer incidence and recurrence: nutrition and lifestyle.

Catalog

Books, media, physical & digital resources